1. Successful Treatment of Disseminated Fusariosis in a 15-Month-old Boy With Refractory Acute Lymphoblastic Leukemia Using High-dose Voriconazole.
- Author
-
Petrikkos L, Kourti M, Stathi A, Antoniadi K, Ampatzidou M, Stefanaki K, Zachariadou L, Iosifidis E, Roilides E, and Polychronopoulou S
- Subjects
- Humans, Male, Infant, Immunocompromised Host, Fusarium drug effects, Treatment Outcome, Voriconazole therapeutic use, Voriconazole administration & dosage, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications, Antifungal Agents therapeutic use, Antifungal Agents administration & dosage, Fusariosis drug therapy, Fusariosis diagnosis
- Abstract
Background: Infections due to rare molds, such as Fusarium spp., cause severe and difficult-to-control diseases with increasing frequency. Data on fusariosis in children and on the use of voriconazole (VCZ), considered a drug of choice, are scarce in infants and children <2 years of age., Case Presentation: We present the first, to our knowledge, pediatric case of disseminated mycosis due to Fusarium musae in a 15-month-old boy with relapsed/refractory acute lymphoblastic leukemia, diagnostics and outcome. Herein, at this severely immunocompromised patient, after prompt diagnosis, disseminated fusariosis was successfully treated with high-dose VCZ at a final dose of 15 mg/kg of body weight twice a day. This occurred by achieving adequate drug exposures as determined by drug susceptibility testing and followed by therapeutic drug monitoring without observed toxicity., Conclusions: Appropriate diagnostic approach and timely administration of optimal antifungal therapy with VCZ were important for the successful treatment of disseminated fusariosis. Therapeutic drug monitoring, especially in <2-year-old children, is necessary to achieve sufficient drug exposure for optimal therapeutic response without toxicity., Competing Interests: Emmanuel Roilides received research grants from Merck, Abvie, Shionogi, Cidara and Pfizer, Inc, to his institution and is a scientific advisor and a member of the Speaker Bureau for Gilead, Merck, Shionogi, Mundipharma and Pfizer, Inc. The remaining authors have no conflicts of interest to disclose., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF